key: cord-0804198-teq31apw
authors: Velez, Juan Carlos Q.; Caza, Tiffany; Larsen, Chirstopher P.
title: COVAN is the new HIVAN: the re-emergence of collapsing glomerulopathy with COVID-19
date: 2020-08-04
journal: Nat Rev Nephrol
DOI: 10.1038/s41581-020-0332-3
sha: f68bf62cb99cc85e162606526c01330553e08c2b
doc_id: 804198
cord_uid: teq31apw

Reports of collapsing glomerulopathy in patients of African ancestry and high-risk APOL1 genotype infected with SARS-CoV-2 have emerged during the COVID-19 pandemic. This new entity, which we term COVID-19-associated nephropathy (COVAN), may particularly impact individuals in some regions of the world. Awareness of this potentially ominous complication of COVID-19 must be raised.

Individuals of African ancestry are at increased risk of chronic kidney disease (CKD) and kidney failure owing to the presence of polymorphisms in the apolipi protein L1 (APOL1) gene 1 . Approximately 14% of the African American population are homozygous for the G1 or G2 APOL1 risk alleles. Although these genetic variants explain a substantial proportion of the increased burden of CKD and kidney failure in African Americans, most individuals who carry two APOL1 risk alleles do not develop kidney disease 2 . When disease does develop, it has a wide clinical spectrum ranging from arterio nephrosclerosis with slowly progressive kidney disease to the most fulminant form, collapsing glomerulopathy, which is associated with a high risk of irreversible and rapid progression to kidney failure 1 . Notably, the highest risk conveyed by two APOL1 risk alleles is seen when certain diseases act as 'second hits' and trigger collapsing glomerulopathy (Supplementary Table 1 Table 1) . A com mon denominator for many aetiologies of collapsing glomerulopathy is the activation of interferon. In fact, endothelial tubuloreticular inclusions, which have been described as 'interferon footprints' , are commonly iden tified ultrastructurally within glomeruli of individuals with collapsing glomerulopathy.

Further supporting a connection between interferon and APOL1, interferon therapy used for the treatment of hepatitis C viral infection has been reported to cause collapsing glomerulopathy in patients who are homozy gous for APOL1 risk alleles (Supplementary Table 1 ). Moreover, cases of collapsing glomerulopathy have been reported in individuals of African descent with systemic conditions characterized by interferon activa tion, including haemophagocytic lymphohistiocytosis (HLH) and stimulator of interferon genes associated vasculopathy with onset in infancy (STING SAVI) (Supplementary Table 1 ). The precise mechanism by which APOL1-associated glomerulopathy interacts with interferon signalling pathways is unclear. Experimental work has shown that interferon markedly upregulates levels of APOL1, although whether this upregulation occurs directly or via chemokines is unclear 3, 4 . In sup port of a role for chemokines in this process, data from the NEPTUNE cohort demonstrated upregulation of the chemokine gene CXCL9 in glomeruli of high risk APOL1 allele carriers 5 . Once activated by the interferonchemokine pathway, the APOL1 risk variant seems to cause disruption of autophagy and mitochondrial homeo stasis and ultimately induces glomerular epithelial cell death 4 (Fig. 1) .

The current COVID19 pandemic has unveiled a rebirth of reports of collapsing glomerulopathy akin to those seen during the HIV epidemic. To date, five case reports have been published -three from the USA, one from Switzerland and one from Francedescribing cases of collapsing glomerulopathy in asso ciation with SARS CoV2 infection (Supplementary Table 1 Reports of collapsing glomerulopathy in patients of African ancestry and high-risk APOL1 genotype infected with SARS-CoV-2 have emerged during the COVID-19 pandemic. This new entity, which we term COVID-19-associated nephropathy (COVAN), may particularly impact individuals in some regions of the world. Awareness of this potentially ominous complication of COVID-19 must be raised. African ethnicity. Our own report described six patients with SARS CoV2 infection and collapsing glomerulo pathy within the South Gulf region during a COVID19 upsurge in New Orleans, USA 6 . All of these patients were of African descent and had two high risk APOL1 alleles. Clinically, these patients presented with acute kidney injury (AKI) and nephrotic range proteinuria. The observed histopathological lesions resembled those seen in other forms of collapsing glomerulopathy, with segmental to global collapse of the glomerular capil lary tuft, hypertrophy and hyperplasia of the overly ing podocytes and parietal epithelial cells, and protein resorption droplets within hyperplastic glomerular epi thelial cells. Tubulointerstitial lesions typically associ ated with APOL1-related disease, including microcystic tubular dilatation and tubular injury, were also present. No viral particles were identified ultrastructurally and SARS CoV2 was not detected within the kidney biopsy tissue by immunohistochemistry or in situ hybridiza tion. Although it has been proposed that expression of angiotensin converting enzyme 2 (ACE2) in podo cytes could be a port of entry for SARS CoV2 into the glomeruli 7,8 , available evidence does not support that contention. Therefore, the development of collapsing glomerulopathy in patients with COVID19 may fol low a host immune response involving the activation of interferon and chemokines rather than direct infection of glomerular cells (Fig. 1) .

It is now apparent that hyperinflammation is a key driver of disease severity in patients with SARS CoV2 infection. Distinct stages of the immune response have been delineated, starting with an early stage with induction of a potent interferon response, followed by a delayed response that may lead to progressive tissue damage and a third stage characterized by excessive macrophage activation 9 . Although much about the response to SARS CoV2 infection remains unknown, it is clear that immune dysregulation is important for the pathogenesis in patients with severe COVID19 and that the inflammatory milieu is likely similar to those seen in other diseases associated with collapsing glomerulopathy.

Given the emerging reports of collapsing glomer ulopathy associated with COVID19, further studies are needed to assess the relative risk of kidney disease conferred by homozygosity for APOL1 risk alleles in patients with SARS CoV2 infection. If confirmed, this association could have important public health implica tions in certain geographical regions. Beyond the initial episode of AKI, the long term consequences are uncer tain. APOL1 genotyping could easily be deployed for prognostication and/or to identify patient populations that might benefit from early initiation of antiviral or anti cytokine therarapeutics, although clinical trials are urgently needed to identify agents with proven efficacy and acceptable safety profile. Conversely, the identifi cation of patients who are homozygous for APOL1 risk alleles could guide against some proposed treatments. For example, a phase II clinical trial in Hong Kong found a triple antiviral therapy consisting of a combination of interferon β1b, lopinavir-ritonavir and ribavirin to be safe and superior to lopinavir-ritonavir alone in patients with COVID19 (reF. 10 ). However, one would hypo thesize that interferon based therapy may not be suitable for use in patients with APOL1 risk alleles, as it could act as a second hit to induce kidney injury.

In summary, collapsing glomerulopathy has emer ged as a distinct global nephropathy associated with SARS CoV2 infection, which seems to specifically affect individuals of African ancestry who are carriers we recommend that carriers of APOL1 risk variants are considered to be at 'particular risk of COVAN' of APOL1 risk variants. Given the clinico pathological resemblance of the collapsing glomerulopathy pheno type with HIVAN and the remarkable parallel between viral infection and susceptibility conferred by genetic background, we propose the term COVID19 associated nephropathy (COVAN) be used to describe this spe cific entity. This type of nephropathy is to be distin guished from most cases of AKI in COVID19, which are characterized by acute tubular injury. In light of the current pandemic and an anticipated second wave of COVID19 in the near future, we expect that we will encounter a growing number of cases of COVAN. This condition should be particularly suspected in patients of African descent who present with COVID19, AKI and nephrotic range proteinuria. Given the race to develop new anti inflammatory and anti cytokine ther apies for COVID19, we recommend that carriers of APOL1 risk variants are considered to be at 'particular risk of COVAN' and suggest that enrolment of these individuals into clinical trials should be prioritized.

Association of trypanolytic ApoL1 variants with kidney disease in African Americans

MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis

Innate immunity pathways regulate the nephropathy gene Apolipoprotein L1

Transgenic expression of human APOL1 risk variants in podocytes induces kidney disease in mice

Integrative genomics identifies novel associations with APOL1 risk genotypes in Black NEPTUNE subjects

Acute kidney injury and collapsing glomerulopathy associated with COVID-19 and APOL1 high risk genotype

Glomerular localization and expression of angiotensinconverting enzyme 2 and angiotensin-converting enzyme: implications for albuminuria in diabetes

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages

Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial

J.C.Q.V. has participated in Advisory Board meetings for Mallinckrodt Pharmaceuticals and Retrophin and is a member of the Speaker Bureau for Otsuka Pharmaceuticals. None of the products related to those engagements are discussed in this manuscript. T.C. and C.P.L are employees of Arkana Laboratories, which is a vendor of APOL1 genotype clinical testing.

Nature Reviews Nephrology thanks V. D'Agati and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

Supplementary information is available for this paper at https://doi.org/ 10.1038/s41581-020-0332-3.